198 related articles for article (PubMed ID: 7623066)
1. Determinants of drug response in camptothecin-11-resistant glioma cell lines.
Matsumoto Y; Fujiwara T; Nagao S
J Neurooncol; 1995; 23(1):1-8. PubMed ID: 7623066
[TBL] [Abstract][Full Text] [Related]
2. Quantitative analysis of DNA topoisomerase I activity in human and rat glioma: characterization and mechanism of resistance to antitopoisomerase chemical, camptothecin-11.
Matsumoto Y; Fujiwara T; Honjo Y; Sasaoka N; Tsuchida T; Nagao S
J Surg Oncol; 1993 Jun; 53(2):97-103. PubMed ID: 8388965
[TBL] [Abstract][Full Text] [Related]
3. [Quantitative analysis of DNA topoisomerase I activity in human and rat glioma: characterization and mechanism of resistance to antitopoisomerase chemical, camptothecin-11].
Matsumoto Y; Fujiwara T; Honjo Y; Sasaoka N; Tsuchida T; Nagao S
Noshuyo Byori; 1994; 11(1):59-64. PubMed ID: 8162152
[TBL] [Abstract][Full Text] [Related]
4. Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody.
Sugimoto Y; Tsukahara S; Oh-hara T; Isoe T; Tsuruo T
Cancer Res; 1990 Nov; 50(21):6925-30. PubMed ID: 2170010
[TBL] [Abstract][Full Text] [Related]
5. Growth inhibitory effect of a new camptothecin analog, DX-8951f, on various drug-resistant sublines including BCRP-mediated camptothecin derivative-resistant variants derived from the human lung cancer cell line PC-6.
Ishii M; Iwahana M; Mitsui I; Minami M; Imagawa S; Tohgo A; Ejima A
Anticancer Drugs; 2000 Jun; 11(5):353-62. PubMed ID: 10912951
[TBL] [Abstract][Full Text] [Related]
6. Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer: characterization and mechanism of resistance.
Kanzawa F; Sugimoto Y; Minato K; Kasahara K; Bungo M; Nakagawa K; Fujiwara Y; Liu LF; Saijo N
Cancer Res; 1990 Sep; 50(18):5919-24. PubMed ID: 2168285
[TBL] [Abstract][Full Text] [Related]
7. Detection of topoisomerase I gene point mutation in CPT-11 resistant lung cancer cell line.
Kubota N; Kanzawa F; Nishio K; Takeda Y; Ohmori T; Fujiwara Y; Terashima Y; Saijo N
Biochem Biophys Res Commun; 1992 Oct; 188(2):571-7. PubMed ID: 1332703
[TBL] [Abstract][Full Text] [Related]
8. A human small cell lung carcinoma cell line, resistant to 4'-(9-acridinylamino)-methanesulfon-m-anisidide and cross-resistant to camptothecin with a high level of topoisomerase I.
Prost S; Riou G
Biochem Pharmacol; 1994 Aug; 48(5):975-84. PubMed ID: 8093110
[TBL] [Abstract][Full Text] [Related]
9. O(6)-methylguanine-DNA methyltransferase (MGMT) as a determinant of resistance to camptothecin derivatives.
Okamoto R; Takano H; Okamura T; Park JS; Tanimoto K; Sekikawa T; Yamamoto W; Sparreboom A; Verweij J; Nishiyama M
Jpn J Cancer Res; 2002 Jan; 93(1):93-102. PubMed ID: 11802813
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of topoisomerase I catalytic activity as determinant of drug response in human cancer cell lines.
Voigt W; Vanhoefer U; Yin MB; Minderman H; Schmoll HJ; Rustum YM
Anticancer Res; 1997; 17(5A):3707-11. PubMed ID: 9413228
[TBL] [Abstract][Full Text] [Related]
11. Establishment and characterization of human gastric and colonic xenograft lines resistant to CPT-11 (a new derivative of camptothecin).
Nagai S; Yamauchi M; Andoh T; Nishizawa M; Satta T; Kodera Y; Kondou K; Akiyama S; Ito K; Takagi H
J Surg Oncol; 1995 Jun; 59(2):116-24. PubMed ID: 7776652
[TBL] [Abstract][Full Text] [Related]
12. Establishment of a CPT-11-resistant human ovarian cancer cell line.
Kijima T; Kubota N; Nishio K
Anticancer Res; 1994; 14(3A):799-803. PubMed ID: 8074481
[TBL] [Abstract][Full Text] [Related]
13. Identification and characterization of a deletion mutant of DNA topoisomerase I mRNA in a camptothecin-resistant subline of human colon carcinoma.
Yanase K; Sugimoto Y; Tsukahara S; Oh-Hara T; Andoh T; Tsuruo T
Jpn J Cancer Res; 2000 May; 91(5):551-9. PubMed ID: 10835501
[TBL] [Abstract][Full Text] [Related]
14. Retroviral expression of a mutant (Gly-533) human DNA topoisomerase I cDNA confers a dominant form of camptothecin resistance.
Yanase K; Sugimoto Y; Andoh T; Tsuruo T
Int J Cancer; 1999 Mar; 81(1):134-40. PubMed ID: 10077164
[TBL] [Abstract][Full Text] [Related]
15. DX-8951f, a water-soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN-38-resistant variant.
Joto N; Ishii M; Minami M; Kuga H; Mitsui I; Tohgo A
Int J Cancer; 1997 Aug; 72(4):680-6. PubMed ID: 9259410
[TBL] [Abstract][Full Text] [Related]
16. A Novel Camptothecin Derivative 3j Inhibits Nsclc Proliferation Via Induction of Cell Cycle Arrest By Topo I-Mediated DNA Damage.
Liu Y; Zhang J; Feng S; Zhao T; Li Z; Wang L; Wang P; Du H; Yuan S; Sun L
Anticancer Agents Med Chem; 2019; 19(3):365-374. PubMed ID: 30523769
[TBL] [Abstract][Full Text] [Related]
17. Low-level resistance to camptothecin in a human small-cell lung cancer cell line without reduction in DNA topoisomerase I or drug-induced cleavable complex formation.
Sorensen M; Sehested M; Christensen IJ; Larsen JK; Jensen PB
Br J Cancer; 1998 Jun; 77(12):2152-61. PubMed ID: 9649127
[TBL] [Abstract][Full Text] [Related]
18. Camptothecin analogues with enhanced antitumor activity at acidic pH.
Adams DJ; Dewhirst MW; Flowers JL; Gamcsik MP; Colvin OM; Manikumar G; Wani MC; Wall ME
Cancer Chemother Pharmacol; 2000; 46(4):263-71. PubMed ID: 11052623
[TBL] [Abstract][Full Text] [Related]
19. Characterization of a human small-cell lung cancer cell line resistant to a new water-soluble camptothecin derivative, DX-8951f.
Nomoto T; Nishio K; Ishida T; Mori M; Saijo N
Jpn J Cancer Res; 1998 Nov; 89(11):1179-86. PubMed ID: 9914787
[TBL] [Abstract][Full Text] [Related]
20. Delta-24 increases the expression and activity of topoisomerase I and enhances the antiglioma effect of irinotecan.
Gomez-Manzano C; Alonso MM; Yung WK; McCormick F; Curiel DT; Lang FF; Jiang H; Bekele BN; Zhou X; Alemany R; Fueyo J
Clin Cancer Res; 2006 Jan; 12(2):556-62. PubMed ID: 16428500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]